Literature DB >> 6968154

Large dose procainamide therapy for ventricular tachyarrhythmia.

A M Greenspan, L N Horowitz, S R Spielman, M E Josephson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6968154     DOI: 10.1016/0002-9149(80)90015-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  8 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs. Rationale and current status.

Authors:  R Latini; A P Maggioni; A Cavalli
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

2.  Recent trends in the management of life-threatening ventricular arrhythmias.

Authors:  B N Singh; J N Weiss; K Nademanee; J H Wittig; P Guzy
Journal:  West J Med       Date:  1984-11

Review 3.  Therapeutic drug monitoring of antiarrhythmic agents.

Authors:  J E Brown; D G Shand
Journal:  Clin Pharmacokinet       Date:  1982 Mar-Apr       Impact factor: 6.447

Review 4.  Practical optimisation of antiarrhythmic drug therapy using pharmacokinetic principles.

Authors:  J L Bauman; M D Schoen; T J Hoon
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

Review 5.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

Review 6.  Reliability of antiarrhythmic drug plasma concentration monitoring.

Authors:  F Follath; U Ganzinger; E Schuetz
Journal:  Clin Pharmacokinet       Date:  1983 Jan-Feb       Impact factor: 6.447

7.  Immunomodulatory effect of procainamide in man. Inhibition of human suppressor T-cell activity in vitro.

Authors:  T Ochi; E A Goldings; P E Lipsky; M Ziff
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

8.  A comparison of sotalol and procainamide in symptomatic ventricular tachycardia.

Authors:  L J Jordaens; F Colardyn; D L Clement
Journal:  Cardiovasc Drugs Ther       Date:  1989-04       Impact factor: 3.727

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.